A 200-Mile Run for Multiple Myeloma

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.

In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.

Having social media platforms to share breast cancer experiences changes the narrative for others who may empathize, a survivor and advocate said.

When I told my friends and family I have multiple myeloma, some of them didn't know what to do.